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Abstract
Introduction: Psoriasis, a systemic disease with a chronic course, is associated with a 
high degree of comorbidities and decreased quality of life.
Aims: The aims of the study were to analyze epidemiological data of a large cohort of 
patients diagnosed with psoriasis over 8 years and to assess factors related to psoriasis 
severity and impact on quality of life.
Research methods: A transversal study was performed on 1236 persons diagnosed with 
psoriasis in an OutPatient Dermatology Center between January 1, 2004 and December 
31, 2011.
Clinical examination was done and medical records were complied including: type of 
psoriasis, number of body locations at the onset and at the moment of examination, 
severity index, family history of psoriasis, comorbidities, past and current treatments, 
demographic characteristics, residence, level of education, working status and income, 
smoking, and alcohol intake. Linear regression was used for multivariable analysis.
Key results of the chapter: Comorbidities were present in 36.1% of patients with mild 
form of psoriasis, 44.05% with moderate forms, and in 19.64% of severe psoriasis.
Onset and clinical examination age, education level, residence, job, gender, and smoking 
were significant factors associated with severity of psoriasis.
Keywords: psoriasis, epidemiological data, comorbidities, risk factors, severity index
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1. Introduction
One of the most common T-cell-mediated diseases, psoriasis, is widely spread, potentially 
affecting 125 million people, or nearly 3% of the world’s population [1–3]. Reports show that 
psoriasis affects as much as 2% of the UK population [4]. A significant number of UK psoriatic 
patients have a Dermatology Life Quality Index (DLQI) of >10, indicating that the disease 
strongly affects their lives [4]. Social factors such as stigmatization, psychological factors such 
as depression, and physical factors such as pruritus, pain, and other comorbidities have a 
great impact on the patient’s life [5, 6].
Psoriasis involves high costs in the health-care system, represented by diagnosis, psy-
chological counseling, investigations, treatments, and further research, which cannot 
be entirely quantified. A systematic review including 22 studies, published in JAMA 
Dermatology 2015, takes a comprehensive look at the cost of psoriasis in the USA by ana-
lyzing the expenses reported between 2008 and 2013, associated with the disease. In 2013, 
the US cost of psoriasis was estimated around $112 billion. Researchers have described 
four categories of expenses associated with psoriasis. Direct costs represented by doctor’s 
appointments, investigations, and therapies, have the highest expenses, estimated to be 
$8000 annually per person. The cost of dealing with comorbidities such as heart disease 
and depression, extends the costs with almost $5000 per person annually. Indirect costs are 
considered absences from work or lost productivity on the job, caused by psoriasis, and 
estimated to be upwards of $4000 annually per person. The decreased quality of life with 
reduced selfconfidence and substantial stigmatization cannot be quantified or calculated in 
terms of cost—impalpable costs. US psoriatic patients would pay a lifetime cost of $11,498 
for treatment, relief of physical symptoms, emotional health, and reintegration into society. 
The direct psoriasis costs ranged from $51.7 to $63.2 billion, the indirect costs ranged from 
$23.9 to $35.4 billion, and medical comorbidities were estimated to be $36.4 billion in 2013 
[7]. On the strength of such high costs and the burden of seeking the right therapy, it is 
of great importance to assess psoriatic patients with comorbidities associated with severe 
disease and decreased quality of life.
Recent studies show that psoriatic patients have relatively higher risks of heart disease, 
stroke, hypertension, and diabetes. Furthermore, due to social isolation, patients are 
more prone to develop depression and anxiety compared to the general population [4–6, 
8]. A national study in Taiwan performed on 51,800 patients diagnosed with psoriasis 
revealed a high prevalence ratio (relative risk (RR); [95% confidence interval (CI)]) for 
rheumatoid arthritis (3.02; [2.68, 3.41]), alopecia areata (4.71; [2.98, 7.45]), vitiligo (5.94; 
[3.79, 9.31]), pemphigus (41.81; [12.41, 140.90]), pemphigoid (14.75; [5.00, 43.50]), heart 
disease (1.32; [1.26, 1.37]), hypertension (1.51; [1.47, 1.56]), hyperglyceridemia (1.61; [1.54, 
1.68]), diabetes (1.64; [1.58, 1.70]), hepatitis B viral infection (1.73; [1.47, 2.04]), hepatitis 
C viral infection (2.02; [1.67, 2.44]), systemic lupus erythematosus (6.16; [4.70, 8.09]), sleep 
disorder (3.89; [2.26, 6.71]), asthma (1.29; [1.18, 1.40]), allergic rhinitis (1.25; [1.18, 1.33]), 
chronic  airways obstruction (1.47; [1.34, 1.61]), lip, oral cavity, and pharynx cancer (1.49; 
[1.22, 1.80]), digestive organs and peritoneum cancer (1.57; [1.41, 1.74]), and depression 
(1.50; [1.39, 1.61]) [8].
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Psoriasis, a systemic disease with a chronic course, is associated with a high degree of comor-
bidities and decreased quality of life.
Psoriasis can vary tremendously in its severity. A number of studies  investigated the factors 
that affect severity [9, 10]. They reported significant associations between psoriasis severity 
and comorbid diseases [10], male gender, younger age [11, 12], localization of the lesions [13], 
the presence of family history of psoriasis [14], smoking, and alcohol  consumption [15]. The 
factors that affect severity are still not well characterized.
2. An overview of the transversal study
2.1. Aims and objectives of the study: methods and materials
The aim of this study was to evaluate clinical and epidemiological characteristics of the 
 psoriatic population for establishing prevention strategies and optimal clinical management.
The objectives of this transversal study were to analyze epidemiological data of a large 
cohort of patients diagnosed with psoriasis over a period of 8 years and to assess factors 
related to psoriasis severity and impact on their quality of life (validated by Psoriasis Area 
and Severity Index (PASI) index and DLQI).
All the investigations were conducted in an outpatient clinic specialized for psoriasis and 
investigative dermatology, in the north-eastern region of Romania, over a period of 8 years. 
Study was performed on 1236 persons diagnosed with psoriasis between January 1, 2004 and 
December 31, 2011.
Participants were examined for psoriasis by the same two dermatologists, under similar 
conditions. All patients had a complete physical examination and their medical history was 
recorded.
Psoriasis was diagnosed by dermatological examination and was confirmed by punch skin 
biopsy, when needed. Skin biopsies were performed at a representative psoriatic plaque of 
each patient.
In other articles [16, 17], psoriasis is classified as mild, moderate, and severe, based on clini-
cal evaluation tools such as the extent of the affected skin surface. In this study, in order to 
quantify the severity of the disease, PASI was used; patients were categorized into mild (PASI: 
0.0–4.0), moderate (4.1–9.9), and severe (10 or higher) psoriasis.
Patient data and medical history were collected from the Specialized Psoriasis Clinic, over a 
period of 8 years. Written informed consent was obtained from all patients.
The data collected by our dermatologists included the following:
1. demographic characteristics: gender, date of birth, age of the patients at the moment of 
examination, level of education, occupation (jobs distribution, respectively, socioeconomic 
status), residence;
Clinical and Epidemiological Factors Predicting the Severity of Psoriasis
http://dx.doi.org/10.5772/intechopen.68728
125
2. psoriasis—clinical-related data: family history of psoriasis, age distribution at the onset of 
psoriasis, distribution of psoriatic lesions at the moment of diagnosis and at the moment of 
clinical inspection, number of areas involved, symptoms such as pruritus;
3. comorbidities such as thyroid abnormalities, cardiovascular disease (CVD), hypertension, 
other concomitant skin disorders, and others;
4. severity of lesions in relation to evolution characteristics: smoking history, alcohol con-
sumption, past and current therapies with topical steroids.
2.1.1. Statistical analysis
All statistical analyses were conducted using Statistical Analysis System software.
Patient data were presented as proportions, standard deviations, means, and ranges. Linear 
regression was used for multivariable analysis of factors affecting psoriasis severity. Specified 
variables were included in the analysis of index severity. Spearman’s rank coefficient of 
 correlation was used as a nonparametric measure of dependence. Pearson’s chi-squared test 
to quantify differences was used. All statistical tests had a confidence interval of 95% and the 
significance level was set at p < 0.05.
2.2. Results and discussion
2.2.1. Demographic data
2.2.1.1. Gender distribution
Out of the 1236 patients diagnosed with psoriasis, 669 were men (54.13%) and 567 (45.87%) 
were women, showing a predominance of male over female gender (1.18/1).
2.2.1.2. Age distribution at the moment of examination
The highest incidence of the disease was noticed for the age group 30–50 years old (43.12%); 
the minimal incidence was over 70 years (5.83%) and under 20 years (5.5%). Statistically 50% of 
cases were over 40 years and 25% under 33 years.
The median value for age was 44.94 ± 15.84 standard deviation (SD), with a great variability 
from 6 to 91 years old. Psoriasis can occur at any age; patients should seek medical advice 
regardless of age.
2.2.1.3. Distribution of cases reported to residence
As shown in Table 1, urban patients prevail. People living in villages have low incidence of 
psoriasis, reflecting a real reduced number of cases or a smaller addressability to medical care 
(Figure 1).
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2.2.1.4. Level of education
The level of education correlates with the prevalence of psoriasis (Table 2). This can be 
explained by stress, underlying the western modern lifestyle.
2.2.1.5. Occupational characteristics at the moment of medical examination: jobs distribution, 
respectively, socioeconomic status
Present data confirm the high prevalence of psoriasis in working people, especially in stress-
ful activities: engineers, students, professors, managers, drivers, salesmen, and medical staff. 
Physical activity, alcohol consumption, smoking, pollution from the working place, repeated 
trauma, and irritants are linked to psoriasis on workers.
Residence Nr. cases %
Urban 1036 83.82
Rural 200 16.18
Total 1236
Table 1. Results of the study: number of patients reported to residence.
Figure 1. Results of the study: distribution of cases reported to residence.
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Retired persons encounter a frequent diagnosis of psoriasis after a long evolution of the dis-
ease (psoriasis march), even though they allocate time and money in search of medical help. 
This can be explained by the fact that chronic infections, comorbidities, and drug administra-
tion could be a potential trigger for psoriasis flares.
2.2.2. Diagnosis of psoriasis and clinical data
2.2.2.1. Family history of psoriasis
Out of the 1236 patients, a positive family history of psoriasis was found in 380 patients (59.37%); of 
these, 174 (27.18%) had at least one parent with psoriasis, with a λR of 13.59, while 106 patients 
(16.56%) had at least one second-degree relative with psoriasis, and 34 patients (5.31%) had 
one-third-degree relative with psoriasis (Figure 2). No parent-of-origin effect in transmission 
of psoriasis from affected parent to offspring was observed, and there were no significant 
differences in the clinical profiles of the disease between patients grouped by transmission 
pattern of psoriasis.
2.2.2.2. Age of the patients at the onset of psoriasis
Results of the study showed the following: 7.77% of patients did not recall the age at which 
the first lesions appeared, 46.04% had the first diagnosis of psoriasis somewhere between 10 
and 30 years old, and the fewest cases were detected over the age of 50 (11.17%).
The median age at the diagnosis is 29.34 ± 15.24 SD, with the youngest patient being 6 months 
(neonatal psoriasis) and oldest 76 years.
Statistically 50% of cases were less than 27 years old at the moment of first medical seek and 
25% over 39 years old when they accepted psoriasis as a diagnosis (Table 3). Within this 
group, there were 104 cases (8.41%) with the onset of psoriasis under the age of 10 and 263 
(21.28%) of cases had the first certified diagnosis of psoriasis before 19 years old. The majority 
of cases were adult psoriasis 869 (70.31%).
Level of education Nr. cases %
Middle school 54 4.37
College 148 11.97
Vocational school 48 3.88
High school 345 27.91
Postsecondary school 47 3.80
Students 182 14.72
University graduates 412 33.33
Total 1236
Table 2. Results of the study: level of education among patients diagnosed with psoriasis.
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Psoriasis has been reported as a chronic disease that begins in one-third of the patients dur-
ing the first two decades of life [18]. Several prevalence studies have published their results 
showing that one-third of psoriatic patients develop the disease during childhood [19]. A fast 
increase in the incidence rate of psoriasis until the age of 30–35 years was recently reported [20].
Childhood onset of psoriasis was not proven to be a risk factor for higher frequencies of 
 cardiovascular and metabolic comorbidities during adulthood in a recent French study 
[21]. Moreover, the age of onset of psoriasis had no impact on the severity of the disease in 
another retrospective study conducted in Greece [22]. No evidence was found that under 
18 years may influence the disease severity in later life [23].
Figure 2. Results of the study: family history reported.
Onset age (years) Nr. cases %
Age ≤10 104 8.41
10 < age ≤19 263 21.28
Over 20 869 70.31
Table 3. Results of the study: age of the patients at the onset of psoriasis.
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Similar data have been obtained by present analysis: 70.31% of patients enrolled in the study 
were diagnosed after the age of 20, only 104 cases (8.41%) had the onset before the age of 10; 
263 (21.28%) of cases were diagnosed between 10 and 19 years old.
Psoriasis in children should not be considered as underreported because parents seek for 
medical care for their children at the first signs of skin injury. Children with psoriatic arthritis 
(PsA) were not included in the study.
2.2.2.3. The distribution of psoriatic lesions at the moment of diagnosis (Single lesion or multiple 
distributions of cutaneous manifestations declared by patients)
The majority of cases (91.18%) had a unique lesion of psoriasis when they were first diagnosed, 
multiple locations being much rarer (8.82%). Among the unique first clinical signs, most of the 
patients (28.07%) reported scalp being involved, followed by elbows (11.89%), palms (7.93%), 
feet (7.12%), and trunk (5.18%). A significant number of persons involved in the study were 
not able to remember the first location of psoriasis (10.36%).
2.2.2.4. The distribution of psoriatic lesions at the moment of clinical inspection (Single lesion or 
multiple distributions of cutaneous manifestations)
The majority of patients (82.85%) had multiple skin lesions at the moment of clinical inspection 
(Table 4).
The distribution of psoriasis was recorded. Active lesions were noted on the scalp, face, trunk, 
anogenital area, arms, legs, hands, feet, or nails, that is, in 10 different locations (Figure 3):
Nr. cases %
Nail psoriasis 165 13.35
Psoriatic arthritis 309 25.00
Koebner phenomena 173 14.00
Scalp psoriasis 681 55.10
Gutate psoriasis 146 11.81
Superior limbs 788 63.75
Inferior limbs 736 59.55
Trunk 462 37.38
Face 55 4.45
Palmo-plantar 205 16.59
Others 265 21.44
Total 1236
Table 4. Results of the study: distribution of multiple skin lesions at the moment of clinical inspection.
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2.2.2.5. Number of areas involved at the moment of clinical inspection (By single or multiple 
cutaneous lesions)
Out of the 1236 patients enrolled in the study, an approximately equal distribution was observed 
among patients with solitary lesion or two, three, or four body areas involved (Table 5). 
More generalized forms were very rare (Figure 4).
2.2.2.6. Evolution of psoriatic lesions from diagnosis to present clinical inspection
Few patients (1.21%) with multiple onset lesions later turned to have unique lesions, while 
7.61% of them preserved the initial multiple lesions; 15.94% of patients with onset single lesions 
remained with a unique cutaneous psoriasis stigma (the same of different location) (Table 6).
The vast majority of cases (75.24%) with declared unique psoriatic lesion at the onset of the 
disease developed multiple skin manifestations over short or long periods of time.
The statistical report shows no marked relationship between the lesions location at the time 
of the first diagnosis of psoriasis and at the moment of onset evaluation (r = 0.1406, χ2 = 1.018, 
p = 0.312, 95% CI).
The comparison between unique onset lesion and multiple lesions at the moment of clinical 
examination is presented in (Table 7).
2.2.2.7. Symptoms: pruritus and psoriasis
Previous dermatology dogma suggested that atopic dermatitis is itchy and psoriasis is not!
Figure 3. Distribution of multiple skin lesions at the moment of clinical inspection.
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The aim of the present study was to assess the incidence of pruritus in patients diagnosed 
with psoriasis (Figure 5); data were collected based on patients’ responses and pruritus was 
certified by declaration.
Figure 4. Body areas frequently involved.
Location Nr. cases %
Unique lesion 212 17.15
Multiple lesions 1024 82.85
Two body areas 266 21.55
Three body areas 244 19.74
Four body areas 240 19.41
Five body areas 155 12.54
Six body areas 76 6.15
Seven body areas 30 2.43
Eight body areas 12 0.97
10 body areas 1 0.08
Total 1236
Table 5. Number of areas involved.
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Onset unique lesion Nr. cases % Associations of 
multiple lesions at the 
onset of evaluation
Nr. cases %
Unknown 128 10.36 Scalp, auxiliary 1 0.08
Scalp 347 28.07 Scalp, presternal 2 0.16
Elbows 147 11.89 Scalp, elbows 9 0.73
Palms 98 7.93 Scalp, elbows, knees 1 0.08
Feet 88 7.12 Scalp, face 3 0.24
Trunk 64 5.18 Scalp, knees 2 0.16
Hands 51 4.13 Scalp, intraauricular 3 0.24
Knees 34 2.75 Scalp, feet 1 0.08
Goutate 23 1.86 Scalp, buttocks 1 0.08
Abdomen 18 1.46 Scalp, trunk 5 0.40
Fingers 16 1.29 Trunk, axillary 1 0.08
Plantar 16 1.29 Trunk, face 1 0.08
Face 12 0.97 Trunk, palms 1 0.08
Thighs 11 0.89 Trunk, fingers 1 0.08
Retroauricular 11 0.89 Trunk, knees 1 0.08
Perimaleolar 10 0.81 Elbows, palms 5 0.40
Erythrodermic 9 0.73 Elbows, knees 42 3.40
Periumbilical 9 0.73 Elbows, palms 2 0.16
Occipital 6 0.49 Elbows, feet 4 0.32
Cervical 8 0.64 Elbows, plantar 1 0.08
Palpebral 4 0.32 Palms, fingers 1 0.08
Retrooccipital 4 0.32 Palms, pretibial 1 0.08
Genital 3 0.24 Palms, dorsal aspect 
of the hands
1 0.08
Buttocks 3 0.24 Palms, occipital 1 0.08
Preauricular 2 0.16 Palmo-plantar 6 0.49
Lumbo-sacral 2 0.16 Knees, plantar 1 0.08
Temporal 2 0.16 Knees, pretibial 2 0.16
Frontal 1 0.08 Knees, dorsal 
aspects of the hands
1 0.08
Knees, buttocks 1 0.08
Dorsal aspects of the 
hands, feet
4 0.32
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Pruritus was admitted by 293 persons (23.7%) and denied by 943 (76.3%). The presence and 
intensity of pruritus were independent of age, gender, marital status, family history of psoria-
sis, job, level of education, type of psoriasis, alcohol, smoking, duration of the disease, number 
of lesions, and severity index.
Pruritus may be unrecognized and underestimated by the patients and/or medical staff.
2.2.3. Comorbidities
2.2.3.1. Comorbidities: overview
Comorbidities present at the moment of diagnosis and/or in the medical history of patients 
(Figure 6, Table 8).
Out of the 1236 patients enrolled in the study, 59.22% (732 psoriatic patients) had no comor-
bidities at the moment of diagnosis or in their medical history (Table 8).
2.2.3.2. Comorbidities: psoriasis and psoriatic arthritis
Psoriatic arthritis is a chronic, inflammatory, seronegative form of arthritis occurring in subjects 
with psoriasis. PsA usually occurs over the age of 40 and it affects both sexes equally [24, 25].
Onset unique lesion Nr. cases % Associations of 
multiple lesions at the 
onset of evaluation
Nr. cases %
Dorsal aspects of the 
hands, face
1 0.08
Plantar, abdomen 1 0.08
Cervical, 
retroauricular
1 0.08
Total 1127 Total 109
Table 6. Number of areas involved.
Onset location Location at the moment of examination Total
Unique location Multiple locations
ONSET: unique location 197 930 1127
15.94% 75.24%
ONSET: multiple location 15 94 109
1.21% 7.61%
Total 212 1024 1236
Table 7. The number of psoriatic lesions found in time of diagnosis as compared with the number found at clinical 
inspection.
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The incidence and prevalence of PsA among patients with psoriasis varies between different 
studies based on the variety of criteria and methods used to study PsA such as patient history, 
questionnaires, Moll and Wright or Caspar and Grappa classification criteria [26]. Prey et al. 
published a review where prevalence ranged from 2.04 to 26% and 5.94 to 25% when evaluat-
ing PsA using only rheumatologic diagnostic criteria [26].
Likewise, geographical variations in PsA were notified: Europe and North America present 
higher PsA prevalence ranging between 20.6 and 30% compared with Asia where PsA is sig-
nificantly lower (8.7%) as seen in a large study of 1149 patients, in Argentina the prevalence 
rate was found to be 17%, whereas in Brazil 35% [27–31].
Figure 5. Results of the study: pruritus and psoriasis.
Figure 6. The number of patients with present/absent comorbidities at the moment of diagnosis and/or in their medical 
history.
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Comorbidities N % Comorbidities N % Comorbidities N %
Absent 732 59.22 Chronic urticaria 2 0.16 Allergic rhinitis 1 0.08
Arterial hypertension 124 9.92 Lyell syndrome 1 0.08 Sinusitis 2 0.16
Cardiac dysrhythmia 18 1.44 Quincke edema 1 0.08 Hay fever 1 0.08
Ischemic heart disease 20 1.16 Acne 1 0.08 Gilbert syndrome 1 0.08
DZ II 47 3.79 Amygdalectomy 10 0.80 Chronic pancreatitis 3 0.24
DZ insulin-dependent 3 0.24 Adenoidectomy 13 1.04 Hiatal hernia 1 0.08
Dysmetabolic syndrome 18 1.44 Colecystectomy 16 1.28 Umbilical hernia 2 0.16
Morbid obesity 16 1.28 Splenectomy 1 0.08 Chronic cholecystitis 8 0.65
Chronic hepatitis B 10 0.08 Hysterectomy 1 0.08 Biliary lithiasis 4 0.32
Chronic hepatitis C 7 0.56 Ovarectomy 6 0.49 Renal lithiasis 9 0.73
Toxic chronic hepatitis 28 2.24 Inguinal hernia 5 0.40 Chronic pyelonephritis 2 0.16
Liver cirrhosis 2 0.16 Megacolon surgery 1 0.08 Enuresis 1 0.08
Hepatic steatosis 3 0.24 Ischemic stroke 5 0.40 Chronic 
glomerulonephritis
1 0.08
Hepatitis B virus carrier 1 0.08 Infantile paralysis 1 0.08 Chronic urinary tract 
infection
1 0.08
Hepatic cyst hydatid 1 0.08 Status epilepticus 1 0.08 Testicular ectopia 1 0.08
Tuberculosis 12 0.96 Meningitis 1 0.08 Hydrocele 5 0.40
Peptic ulcer 36 2.91 Parkinson disease 1 0.08 Azoospermia 1 0.08
Gastritis 8 0.64 Spastic tetraparesis 1 0.08 Phimosis 2 0.16
Gastric hemorrhage 2 0.16 Cervical cancer 2 0.16 Endometriosis 1 0.08
Disc herniation 21 1.68 Hodgkin disease 1 0.08 Fibroma uterus 14 1.12
Gout 3 0.24 Breast cancer 1 0.08 Ovarian cysts 8 0.64
Rheumatoid arthritis 4 0.32 Cancer colorectal 1 0.08 Fibrocystic breast disease 6 0.49
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Comorbidities N % Comorbidities N % Comorbidities N %
Ankylosing spondylitis 4 0.32 Thyroid cancer 1 0.08 Pituitary adenoma 1 0.08
Rheumatic fever 1 0.08 Gastric cancer 1 0.08 Chronic hypocalcemia 5 0.40
Osteitis 1 0.08 Chronic venous 
insufficiency
15 1.2 Asthma 11 0.88
Psoriatic arthritis 2 0.16 Peripheral arteriopathy 1 0.08 Chronic bronchitis 6 0.49
Knee meniscus graft 1 0.08 Crohn’s disease 1 0.08 Spontaneous 
pneumothorax
1 0.08
Osteomyelitis 2 0.16 Erythematous-pultaceous 
angina
3 0.24 Pleural effusion 1 0.08
Cervical spondylotic 2 0.16 B streptococcal 
pharyngitis
3 0.24 Multiple sclerosis 1 0.08
Autoimmune thyroiditis 1 0.08 Anti-streptolyzin o 2 0.16 Duchenne muscular 
dystrophy
1 0.08
Thyroidectomy
Hypothyroidism
8
9
0.64
0.73
Psychiatric disorders 10 0.80 Myasthenia gravis 1 0.08
Thyroid goiter 3 0.24 keratoconjunctivitis 1 0.08 Vestibular disorder 1 0.08
Vitiligo 10 0.80 Blepharitis
Retinopathy
1
1
0.08
0.08
Secondary amenorrhea 1 0.08
Alopecia areata 2 0.16 Hypermetropia 1 0.08 Gastric prolapse 1 0.08
Dermatomyositis 3 0.24 Glaucoma 1 0.08 Chronic mastoiditis 1 0.08
Rosacea 3 0.24 Cataract 2 0.16 Polyposis coli 2 0.16
Keratosis pilaris 2 0.16 Anemia 3 0.24 Spina bifida 1 0.08
Celiac disease 1 0.08 Idiopathic 
thrombocytopenia
1 0.08
Table 8. General comorbidities among psoriatic patients involved in the study.
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In our study, the estimated PsA prevalence based on rheumatologic evaluation (Moll and 
Wright criteria) was 0.16% among 1236 patients with psoriasis (Table 9), NOT in accord with 
several European revisions.
An extensive study in Germany on 1511 patients revealed a total PsA prevalence of 20.5% [31]. 
In Greece, a retrospective analysis on 278 patients with psoriasis revealed that PsA prevalence 
was 30%. This subgroup of patients with PsA showed significantly higher rates of comorbidities 
including CVD, hypertension, diabetes mellitus type 2, and hypercholesterolemia compared to 
non-PsA patients [24]. Other studies show PsA prevalence ranging between 0.17 and 0.35% in 
the general Greek population [32, 33]. Other two publications report remarkably lower rates of 
PsA prevalence among patients with psoriasis, 7.23% in Croatia, respectively, 9.3% in Serbia [26].
2.2.3.3. Comorbidities: coexistence of psoriasis with other skin diseases at the moment of diagnosis
Out of the 1236 patients enrolled in the study, only 26 psoriatic patients had other skin dis-
eases at the moment of diagnosis (Table 10), including 10 with vitiligo, 3 with dermatomyosi-
tis, 3 with Rosacea, and 2 with Alopecia areata.
2.2.3.4. Comorbidities: coexistence of psoriasis with cardiovascular diseases at the moment of diagnosis
Psoriasis has been associated with high cardiovascular morbidity and mortality. Recent stud-
ies suggest that psoriasis, particularly if severe, has a 58% increased risk of major adverse 
cardiovascular events such as arrhythmia, myocardial infarction, or stroke, and has a 57% 
increased risk of cardiovascular death, beyond the risk of death associated with traditional 
cardiovascular risk factors [34–36].
Of the 1236 patients enrolled in the study, 162 psoriatic patients had cardiovascular diseases 
at the moment of diagnosis (Table 11), great majority accusing arterial hypertension.
Coexistence of rheumatologic diseases Nr. cases %
Disc herniation 21 1.68
Gout 3 0.24
Rheumatoid arthritis 4 0.32
Ankylosing spondylitis 4 0.32
Rheumatic fever 1 0.08
Osteitis 1 0.08
Psoriatic arthritis 2 0.16
Knee meniscus graft 1 0.08
Osteomyelitis 2 0.16
Cervical spondylotic 2 0.16
Total 68/1236
Table 9. Coexistence of psoriasis with other rheumatologic diseases.
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2.2.3.5. Comorbidities: prevalence of thyroid abnormalities among psoriatic patients
Of the 1236 patients diagnosed with psoriasis, only 22 were spotted with thyroid abnormali-
ties (Table 12).
Coexistence of other skin diseases Number of cases %
Vitiligo 10 0.80
Alopecia areata 2 0.16
Dermatomyositis 3 0.24
Rosacea 3 0.24
Keratosis pilaris 2 0.16
Dermatitis herpetiformis 1 0.08
Chronic urticaria 2 0.16
Lyell syndrome 1 0.08
Quincke edema 1 0.08
Acne 1 0.08
Total 26/1236
Table 10. Coexistence of psoriasis with other skin diseases.
Cardiovascular diseases Nr. cases %
Arterial hypertension 124 9.92
Cardiac dysrhythmia 18 1.44
Ischemic heart disease 20 1.16
Total 162/1236
Table 11. Cardiovascular diseases among psoriatic patients involved in the study.
Thyroid abnormalities Nr. cases %
Autoimmune thyroiditis 1 0.08
Thyroidectomy 8 0.64
Hypothyroidism 9 0.73
Thyroid goiter 3 0.24
Thyroid cancer 1 0.08
Total 22/1236 1.77
Table 12. Coexistence of thyroid abnormalities at patients diagnosed with psoriasis.
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2.2.3.6. Comorbidities: psoriasis and tuberculosis
In this transversal study, the incidence of tuberculosis was quantified from the medical his-
tory and at the moment of the clinical examination for patients diagnosed with psoriasis. Of 
the 1236 patients diagnosed with psoriasis, over a period of 8 years (2004–2011) comorbidities 
were present in 40.78% of cases, and 12 of them (0.97%) had a history of tuberculosis: 5 were 
men (41.67%), 8 cases of pulmonary tuberculosis (66.67%), 2 pleural effusions (16.67%), 1 gen-
ital tuberculosis (8.34%), and 1 case of kerato-conjunctivitis (8.34%). Of the 12 patients with 
psoriasis and past tuberculosis, 1 had arterial hypertension and chronic nephritis, 1 obesity, 
1 erythema nodosum, and 1 with gastric carcinoma (Figure 7).
Psoriasis could represent an independent risk factor for tuberculosis, because a high  prevalence 
was reported in recent studies: 18.0%—Bordignon et al. [37]. In another study, latent tubercu-
losis infection was more reported in psoriasis (50%) than inflammatory bowel disease patients 
(24.2%), prior to the onset of any anti-tumor necrosis factor (TNF)-α treatment [38].
2.2.4. Evolution characteristics
2.2.4.1. Severity of lesions in relation to risk factors
The number of psoriatic lesions is in direct relation with the risk factors, including residence, 
gender, index severity, presence of comorbidities, alcohol intake, smoking, work status, and 
family history of psoriasis (Table 13).
2.2.4.2. Severity of lesions in relation to risk factors: smoking and psoriasis
Most of the patients enrolled in the study were nonsmokers, by declaration (Figure 8) but there 
is a significant correlation between the smoking and the severity of the disease (r = 0.254, 
χ2 = 10.49, p = 0.00527, 95% CI).
Figure 7. Tuberculosis among psoriatic patients involved in the study.
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2.2.4.3. Severity of lesions in relation to risk factors: alcohol intake (by declaration) and psoriasis
Of 1236 patients with psoriasis, alcohol consumption was declared by 410 persons, represent-
ing 33.17% of all (Table 14).
Location
Unique lesion Multiple lesions
Nr. patients % Nr. patients %
Urban residence 192 18.53 844 81.47
Rural residence 20 10 180 90
Male gender 103 15.40 566 84.60
Female gender 109 19.22 458 84.60
Mild psoriasis 132 24.63 404 75.37
Moderate psoriasis 65 13 435 87.00
Severe psoriasis 15 7.5 185 92.50
Comorbidities absent 135 18.44 597 81.56
Comorbidities present 77 15.28 427 84.72
Alcohol consumer 45 10.98 365 89.02
Nonalcohol consumer 167 20.22 659 79.78
Nonsmoker 171 19.06 726 80.94
Smoker 41 12.09 298 87.91
Pupil/student 45 3.64 137 11.08
Worker 130 10.52 622 50.32
Retired 20 1.62 129 10.44
Social assisted 1 0.08 27 2.18
Jobless 16 1.29 109 8.82
Family history absent 150 17.22 721 82.78
First-degree relatives 
diagnosed with psoriasis
38 19.00 162 81.00
Second-degree relatives 
diagnosed with psoriasis
15 13.04 100 86.96
Third-degree relatives 
diagnosed with 
psoriasis
7 19.44 29 80.56
Fourth-degree relatives 
diagnosed with 
psoriasis
2 14.29 12 85.71
Table 13. Number of lesions in relation to risk factors (residence, gender, index severity, presence of comorbidities, 
alcohol intake, smoking, work status, and family history of psoriasis).
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2.2.4.4. Severity of lesions in relation to PASI
The number of psoriasis lesions correlates with (Table 15):
• age at the moment of clinical examination (F = 8.902, p = 0.0029);
• residence in rural area (χ2 = 8.589, p = 0.00338, 95% CI);
• alcohol intake (χ2 = 16.47, p = 0.00005, 95% CI);
• smoking (χ2 = 8.408, p = 0.00373, 95% CI);
• occupation: workers/pupils/students (χ2 = 14.11, p = 0.0069, 95% CI).
Figure 8. Results of the study: smokers and nonsmokers involved in the study.
Alcohol consumption Nr. cases %
Positive 410 33.17
Negative 826 66.83
Total 1236
Table 14. Results of the study: number of patients in relation with alcohol consumption.
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2.2.4.5. Severity of lesions in relation with topical steroids
Topical steroids: most of the patients were several years treated with steroids topically before 
presenting to the clinical appointment (Table 16).
2.3. Correlations with the severity of psoriasis (Risk factors)
Severity index of the disease at the moment of clinical examination (Table 17) are as follows:
Within psoriasis patients, 43.37% were diagnosed with mild form of the disease, 40.45% with 
moderate, and only 16.18% with severe type.
2.3.1. Correlations between demographic data and the severity index of psoriasis
2.3.1.1. Gender distribution versus severity index
There is a strong correlation between gender and severity of the disease (r = 0.378, p = 0.00023, 
χ2 = 16.706, p = 0.00024, 95% CI) (Table 18). Among severe cases, 19.8% were men and only 
11.82% women, in comparison with mild cases where 47.62% were women (Figure 9).
Parameter/factor PASI index-correlation Number of psoriatic 
lesions-correlation
Onset age Yes No
Age at the moment of clinical 
examination
Yes Yes
Gender (male) Yes No
Residence in rural area Yes Yes
History family of psoriasis Yes No
Presence of comorbidities Yes No
Alcohol and smoking Yes Yes
Work status-education Retired persons/jobless Workers/pupils-students
Table 15. Results of the study: severity of lesions in relation to PASI.
Topical steroids Nr. cases %
Yes 1073 86.81
No 110 8.90
Unknown 53 4.29
Total 1236
Table 16. Results of the study: number of patients treated with topical steroids.
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Type of psoriasis Nr. cases %
Severe (PASI > 10) 200 16.18
Moderate (PASI: 3/5–10) 500 40.45
Mild 536 43.37
Total 1236
Table 17. Results of the study: severity index of the disease.
Psoriasis severity Gender of the patient Total
Male Female
Mild 266 270 536
39.76% 47.62%
Moderate 270 230 500
40.36% 40.56%
Severe 133 67 200
19.88% 11.82%
Total 669 567 1236
Table 18. Gender distribution versus severity index.
Figure 9. Gender distribution among patients involved in the study.
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Our data support a male predominance in all forms of psoriasis (54.13% versus 45.87%) and 
greater severity in men (Table 19).
2.3.1.2. Age of patients at the moment of clinical examination versus severity index
The mean (medium) age of patients presents important differences reported to the severity of 
the disease (F = 45.780, p ≪ 0.01, 95% CI) (Figure 10), with small values for mild cases (41.11 ± 
16.07 SD) and greater values for severe cases (53.06 ± 13.82 SD) (Table 20).
df = 2 Chi-square χ2 p 95% confidence interval
Pearson Chi-square—χ2 16.70615 0.00024
M-L Chi-square 16.99982 0.00020
Correlation coefficient (Spearman 
Rank R)
−0.378898 0.00023
Table 19. Results of the study: correlations between gender distribution and the severity index.
Figure 10. Mean (medium) age of patients at the moment of clinical examination.
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Psoriasis is a disease of all ages but predominant around 40 years of age; early psoriasis (man-
ifesting before 40 years of age) is associated with increased severity index, while late psoriasis 
(manifesting after 40 years of age) appears to be milder (Table 21). We do not see the peak 
in the age groups 20–30 and 40–50, but there is a quite uniform distribution starting with the 
age group 20 and ending with age group 60 years old (Figure 11). The most active age group 
30–50 years is affected by psoriasis (Table 22).
Psoriasis Media age Media Dev.std Er.std Min Max Q25 Median Q75
−95% +95%
Severe 53.06 51.13 54.99 13.82 0.98 12.00 88.00 43.50 53.50 63.00
Moderate 45.79 44.47 47.11 15.01 0.67 13.00 91.00 34.00 45.00 57.00
Mild 41.11 39.74 42.47 16.07 0.69 6.00 89.00 29.00 40.00 52.00
All Groups 44.94 44.05 45.82 15.84 0.45 6.00 91.00 33.00 44.00 57.00
Table 20. Age of patients at the moment of clinical examination versus severity index.
F (95% confidence interval) p
Levene Test of Homogeneity of Variances 3.034166 0.048474
Brown-Forsythe Test of Homogeneity of Variances 2.843525 0.058602
Test ANOVA 45.78075 0.000000
Table 21. Test ANOVA—results.
Figure 11. Mean (medium) age of patients at the onset of disease.
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2.3.1.3. Age of the patients at the onset of psoriasis versus severity index
The first diagnosis of psoriasis was made at the age 10–30 for the most of the patients and the 
percentage of psoriasis de novo falls with age (Table 23). This could mean that majority of 
patients were diagnosed previously or they do not seek special care in the older age. Our find-
ings suggest that there is a march over time toward greater severity in the disease.
The medium of age of onset shows statistical differences related to severity of psoriasis (F = 
11.69, p = 0.000009, 95% CI): for mild forms were 27.15 ± 14.92 SD (Table 24), for moderate 
cases 29.95 ± 15.07 SD, and for severe cases 33.17 ± 15.07 SD (Table 25).
Unequal N HSD test p (95% confidence interval)
Mild versus moderate 0.000025
Mild versus severe 0.000022
Moderate versus severe 0.000027
Table 22. Results of the unequal N HSD test: correlations between age of patients and the severity index.
Psoriasis Media age Media Dev.std Er.std Min Max Q25 Median Q75
−95% +95%
Mild 27.15 25.79 28.52 15.20 0.70 1.00 72.00 16.00 25.00 36.00
Moderate 29.95 28.58 31.32 15.07 0.70 0.50 76.00 18.00 27.00 40.00
Severe 33.17 31.07 35.26 14.92 1.06 3.00 70.00 22.00 32.00 43.00
All groups 29.34 28.45 30.22 15.24 0.45 0.50 76.00 18.00 27.00 39.00
Table 23. Age of patients at the onset of psoriasis versus severity index.
F (95% confidence interval) p
Levene Test of Homogeneity of Variances 0.108982 0.896756
Brown-Forsythe Test of Homogeneity of Variances 0.060732 0.941079
Test ANOVA 11.69489 0.000009
Table 24. Test ANOVA—results.
Unequal N HSD test p (95% confidence interval)
Mild versus moderate 0.012604
Mild versus severe 0.000029
Moderate versus severe 0.032170
Table 25. Results of the unequal N HSD test: correlations between age of patients at the onset of psoriasis and the 
severity index.
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2.3.1.4. Distribution of cases reported to residence/location versus severity index
The present study confirms the higher prevalence of psoriasis in urban area, but mild cases 
were diagnosed compared with severe and untreated forms seen in people living in rural 
areas (Figure 12). Explanations can be found in reduced accessibility of people living in vil-
lages far away from a specialized medical center; long period of no treatments especially in 
milder forms considering the disease an esthetic problem rather than a disease; stress-less life, 
open air activity with many hours of sun bathing/exposure; different nutrition habits (less 
industrialized and processed food, less meat, and more vegetables), type of water, skin-care 
practices, tobacco, alcohol, smaller exposure to drugs, and other chemicals (Table 26).
Major association exists between index severity and residence of the patients (r = 0.319, p = 
0.0037, χ2 = 9.507, p = 0.0086, 95% CI). Although the prevalence of psoriasis is higher in urban 
area, mild cases are diagnosed, severe and untreated forms are seen in people living in rural 
areas (Table 27).
2.3.1.5. Level of education versus severity index
High level of education was recognized in patients severely affected by psoriasis. Persons in 
worrying conditions were related to income/job such as retired people, with no income or 
social-assisted developed severe forms of psoriasis (Table 28).
Figure 12. Residence distribution among patients involved in the study.
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df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 9.507847 0.00862
M-L Chi-square 9.698231 0.00784
Correlation coefficient (Spearman Rank R) 0.3191024 0.00317
Table 27. Results of the study: correlations between residence distribution and the severity index.
Psoriasis severity Urban Rural Total
Mild 469 67 536
45.27% 33.50%
Moderate 406 94 500
39.19% 47.00%
Severe 161 39 200
15.54% 19.50%
Total 1036 200 1236
Table 26. Residence versus severity index.
Level of education Psoriasis severity Total
Mild Moderate Severe
Middle school 19 23 12 54
35.19% 42.59% 22.22%
College 46 72 30 148
31.08% 48.65% 20.27%
Vocational school 13 23 12 48
27.08% 47.92% 25.00%
High school 124 158 63 345
35.94% 45.80% 18.26%
Postsecondary school 20 15 12 47
42.55% 31.91% 25.53%
Students 121 56 5 182
66.48% 30.77% 2.75%
University graduates 193 153 66 412
46.84% 37.14% 16.02%
Total 536 500 200 1236
Table 28. Level of education versus severity index.
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Level of education points out a strong correlation with severity (r = −0.413, p ≪ 0.01); patients 
with less than 12 years of school presented more cases with psoriasis type moderate-severe 
(Table 29). Although high educated persons, with university degree are more often diagnosed 
with psoriasis, cases are less severe.
Although higher education suggests a higher prevalence of psoriasis, a lower level of educa-
tion correlates strongly with moderate-severe forms of psoriasis.
Education may be related to multiple confounding factors including alcohol intake, smoking, 
and access to specialized dermatological care.
2.3.1.6. Jobs distribution/income versus severity index
Among pupils and students, the most frequently diagnosed form of psoriasis was mild one 
(66.48%), severe disease being reported to only 2.75%, while persons without any occupation 
presented severe psoriasis 24.16%, respectively, 24% (Table 30). Moderate forms were seen in 
retired persons (43.62%) and jobless (42.4%). Jobless patients had worse severity (χ2 = 66.67, p 
≪ 0.01, 95% CI) (Table 31).
df = 12 Chi-square χ2 p (95% interval de încredere)
Pearson Chi-square—χ2 77.51211 0.00000
M-L Chi-square 85.73127 0.00000
Correlation coefficient (Spearman Rank R) −0.4139638 0.00000
Table 29. Results of the study: correlations between level of education and the severity index.
Job Psoriasis severity Total
Mild Moderate Severe
Pupil/student 121 56 5 182
66.48% 30.77% 2.75%
Employee 313 316 123 752
41.62% 42.02% 16.36%
Retired 48 65 36 149
32.21% 43.62% 24.16%
Social assisted 12 10 6 28
42.86% 35.71% 21.43%
With no income 42 53 30 125
33.60% 42.40% 24.00%
Total 536 500 200 1236
Table 30. Jobs distribution versus severity index.
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2.3.2. Correlations between clinical data and the severity index of psoriasis
2.3.2.1. Family history of psoriasis versus severity index
There was a positive family history of psoriasis in 29.53% of subjects, 16.18% first-degree rela-
tives, 9.30% second-degree, 2.91% third-degree, and 1.13% fourth-degree (Table 32).
A family history of psoriasis was associated with greater disease severity (r = −0.448, χ2 = 
18.32, p = 0.01893, 95% CI) (Table 33).
2.3.2.2. The distribution of (unique/multiple) psoriatic lesions at the moment of clinical inspection 
versus severity index
The results (Table 34) prove the absence of an important correlation between the severity 
index and type of lesions at the onset of psoriasis (unique/multiple lesions) (r = 0.0249, p = 
0.381, 95% CI) (Table 35). One can notice that in 19.27% cases of severe psoriasis, patients 
describe multiple lesions at the first diagnosis (Figure 13).
2.3.3. Correlations between comorbidities and the severity index of psoriasis
2.3.3.1. Presence of general comorbidities versus index severity
Comorbidities were present in 36.1% of patients with mild form of psoriasis, 44.05% with 
moderate forms, and in 19.64% of severe psoriasis (Figure 14, Table 36).
df = 8 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 66.67419 0.00000
M-L Chi-square 73.96201 0.00000
Correlation coefficient (Spearman Rank R) 0.3056883 0.000
Table 31. Results of the study: correlations between jobs distribution and the severity index.
Psoriasis 
severity
Family history Total
Absent First degree Second degree Third degree Fourth degree
Mild 361 95 60 14 6 536
41.45% 47.50% 52.17% 38.89% 42.86%
Moderate 368 79 29 19 5 500
42.25% 39.50% 25.22% 52.78% 35.71%
Severe 142 26 26 3 3 200
16.30% 13.00% 22.61% 8.33% 21.43%
Total 871 200 115 36 14 1236
Table 32. Results of the study: family history versus severity index.
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The results (r = 0.41, χ2 = 18.79, p = 0.00008, 95% CI) confirm a strong association between the 
presence of comorbidities and severity of psoriasis (Table 37).
2.3.3.2. Comorbidities: appendectomy versus index severity
Appendectomy (Table 38, Figure 15) does not correlate with severity index of psoriasis 
(r= −0.0096, χ2=0.967, p = 0.616, 95% CI) (Table 39).
2.3.4. Correlations between evolution characteristics and the severity index of psoriasis
2.3.4.1. Risk factors: alcohol consumption versus index severity
Severe forms of psoriasis were found in patients with declared chronic alcohol intake (21.22%), 
while mild forms were depicted within non-consumers (47.94%) (Table 40, Figure 16).
df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 0.9511274 0.62154
M-L Chi-square 0.9196143 0.63141
Correlation coefficient (Spearman Rank R) 0.0249217 0.38135
Table 35. Correlations between the distribution of (unique/multiple) psoriatic lesions and the severity index.
Psoriasis severity Onset location of psoriasis Total
Unique location Multiple locations
Mild 492 44 536
43.66% 40.37%
Moderate 456 44 500
40.46% 40.37%
Severe 179 21 200
15.88% 19.27%
Total 1127 109 1236
Table 34. Results of the study: distribution of psoriatic lesion(s) versus severity index.
df = 8 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 18.32477 0.01893
M-L Chi-square 19.13866 0.01414
Correlation coefficient (Spearman Rank R) −0.44809 0.011536
Table 33. Results of the study: correlations between family history and the severity index.
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Figure 13. The distribution of (unique/multiple) psoriatic lesions among patients involved in the study.
Figure 14. The distribution of comorbidities among patients involved in the study.
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Statistically, a correlation between alcohol intake and index severity is proved (r = −0.48, χ2 = 
24.30, p ≪ 0.01, 95% CI) (Table 41).
2.3.4.2. Risk factors: smoking versus index severity
Smokers are prone to severe forms of psoriasis (17.7%), and non-smokers with less severe 
ones (Table 42, Figure 17).
Smoking and severity of psoriasis highly correlate (r = 0.254, χ2 = 10.49, p = 0.00527, 95% CI) 
(Table 43).
Psoriasis severity Comorbidities Total
Absent Present
Mild 353 183 536
48.22% 36.31%
Moderate 278 222 500
37.98% 44.05%
Severe 101 99 200
13.80% 19.64%
Total 732 504 1236
Table 36. Results of the study: comorbidities versus severity index.
Psoriasis severity Appendectomy Total
Present Absent
Mild 106 430 536
41.57% 43.83%
Moderate 110 390 500
43.14% 39.76%
Severe 39 161 200
15.29% 16.41%
Total 255 981 1236
Table 38. Results of the study: (comorbidities) appendectomy versus severity index.
df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 18.79107 0.00008
M-L Chi-square 18.86543 0.00008
Correlation coefficient (Spearman Rank R) 0.4108901 0.00001
Table 37. Correlations between comorbidities and severity index.
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2.3.5. Multivariable analysis of factors implicated in severity of psoriasis
In multivariate analysis, age at the moment of clinical examination (r = 0.83, p ≪ 0.01), age 
of onset (r = −0.69, p = 0.000053, 95% CI), education level (r = −0.588, p = 0.0037), residence (r 
= 0.688, p = 0.0156, 95% CI), job (r = 0.671, p = 0.0328, 95% CI), gender (r = −0.45, p = 0.0394, 
95% CI), and smoking (r = 0.597, p = 0.044, 95% CI) were significant factors associated with 
severity of psoriasis (Table 44).
Figure 15. Number of patients with appendectomy among patients involved in the study.
df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 0.9677348 0.61640
M-L Chi-square 0.9633761 0.61774
Correlation coefficient (Spearman Rank R) −0.009627 0.73528
Table 39. Correlations between number of patients with appendectomy and severity index.
Psoriasis severity Alcohol consumption Total
Declared Not declared
Mild 140 396 536
34.15% 47.94%
Moderate 183 317 500
44.63% 38.38%
Severe 87 113 200
21.22% 13.68%
Total 410 826 1236
Table 40. Results of the study: alcohol consumption versus severity index.
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Figure 16. Alcohol consumption among patients involved in the study.
df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 24.30044 0.00001
M-L Chi-square 24.36224 0.00001
Correlation coefficient (Spearman Rank R) −0.489582 0.000
Table 41. Correlations between alcohol consumption and severity index.
Psoriasis severity Smoking Total
Nonsmoker Smoker
Mild 414 122 536
46.15% 35.99%
Moderate 343 157 500
38.24% 46.31%
Severe 140 60 200
15.61% 17.70%
Total 897 339 1236
Table 42. Results of the study: smoking versus severity index.
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Figure 17. Smoking among patients involved in the study.
df = 2 Chi-square χ2 p (95% confidence interval)
Pearson Chi-square—χ2 10.49251 0.00527
M-L Chi-square 10.60180 0.00499
Correlation coefficient (Spearman 
Rank R)
0.252514 0.00417
Table 43. Correlations between smoking and severity index.
Partial correlation 
psoriasis severity versus
Confidence 
interval (Beta)
Std.Err. (Beta) B Std.Err. B t p (95% confidence 
interval)
Intercept −4.43329 10.37951 −0.42712 0.669374
Gender −0.45016 0.031288 −0.9429 0.04574 −2.06153 0.039482
Age at the moment of 
clinical examination
0.831591 0.048523 0.1777 0.00226 7.86419 0.000000
Age of onset −0.692912 0.047558 −0.922 0.00227 −4.05634 0.000053
Multiple lesions 0.023369 0.028032 0.06017 0.07217 0.83367 0.404642
Education −0.588659 0.030502 −0.3359 0.01156 −2.90666 0.003725
Job 0.67100 0.031403 0.4553 0.02131 2.13671 0.032836
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3. Conclusion
Our study has several strengths.
First of all, the study includes a high number of patients with psoriasis followed over a period 
of 8 years: 1236 persons were enrolled in the study.
Second, over a period of 8 years, detailed and updated information regarding a large vari-
ety of factors throughout the cohort follow-up was collected, thus allowing data correlation 
between psoriasis and various factors and/or different comorbidities.
Third, correlation between psoriasis and different factors permitted the investigation of 
potential associations over long durations such as the analysis of the association of psoriasis 
with several different comorbidities, demographic data, psoriasis severity.
Some limitations of this study include the following: it was performed only on Caucasians 
from predominantly the same region in Romania; therefore, generalizing the results to other 
ethnicities may be partial.
The study was conducted in an outpatient clinic specialized for psoriasis over a period of 8 
years, so an increased number of patients diagnosed with psoriasis earlier had to self-report 
medical history with a small proportion of missing data. Despite this retrospective characteris-
tic, the recall and the high completion rate for all questions on psoriasis were highly accurate.
Psoriasis is a common chronic systemic disease (not a simple skin disorder), spread world-
wide, with a reported prevalence varying from 0.09 to 11.43% [39]. Psoriasis can touch any 
age, with a great variability: from 6 to 91 years old. The number of years should not be a rea-
son for medical advice restriction.
This complex disease, with unknown cause, has many trigger factors, unpredictable course, 
severe comorbidities, and a great impact on quality of life. Further research is needed to 
identify these comorbidities and to take into consideration when evaluating the burdens of 
psoriasis such as costs, impact on quality of life, and integration of  psoriatic patient in the 
society,therefore to be able to recommend the best management and treatment.
Partial correlation 
psoriasis severity versus
Confidence 
interval (Beta)
Std.Err. (Beta) B Std.Err. B t p (95% confidence 
interval)
Location 0.68837 0.028427 0.3510 0.05579 2.42157 0.015611
Family history −0.013668 0.028332 −0.01158 0.02400 −0.48244 0.629586
Comorbidities −0.034033 0.028512 −0.00023 0.00019 −1.19362 0.232876
Alcohol −0.052250 0.033016 −0.8041 0.05081 −1.58256 0.113803
Smoking 0.59732 0.029716 0.9691 0.04821 2.01006 0.044662
Table 44. Multivariable analysis of factors implicated in severity of psoriasis.
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